These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 14551502)

  • 21. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
    Benson AB
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
    Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UFT in the treatment of colorectal and breast cancer.
    Sun W; Haller D
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):49-56. PubMed ID: 11219978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoropyrimidines: a critical evaluation.
    Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
    Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
    Yen-Revollo JL; Goldberg RM; McLeod HL
    Clin Cancer Res; 2008 Jan; 14(1):8-13. PubMed ID: 18172246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
    Hoff PM; Pazdur R
    Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-fluorouracil and dihydropyrimidine dehydrogenase.
    Kubota T
    Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral fluoropoyrimidines.
    Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
    Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.
    Minsky BD
    Int J Cancer; 2001 Feb; 96(1):1-10. PubMed ID: 11241325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
    Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
    Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
    Hoff PM; Lassere Y; Pazdur R
    Drugs; 1999; 58 Suppl 3():77-83. PubMed ID: 10711845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
    Levin J; Hohneker J
    Invest New Drugs; 2000 Nov; 18(4):383-90. PubMed ID: 11081574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [S-1 as a single agent for colorectal cancer].
    Eguchi T; Shirao K
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():121-4. PubMed ID: 16897986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Diasio RB
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.